Peptide Receptor Radionuclide Therapy (Lu-177 DOTATATE) in Progressive Neuroendocrine Tumors (NETs): Potential Predictors of Progression Free Survival (PFS)

被引：0
|
作者：
Badawy, Mohmed [1 ]
Johnson, Geoffrey B. [1 ]
Hobday, Timothy [1 ]
Packard, Annie T. [1 ]
Jain, Manoj [2 ]
Halfdanarson, Thorvardur R. [1 ]
Young, Jason R. [1 ]
Thorpe, Matthew P. [1 ]
Eiring, Rachel A. [1 ]
Kendi, Ayse Tuba [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Jacksonville, FL 32224 USA
来源：
PANCREAS | 2022年 / 51卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
C-24
引用
收藏
页码：E42 / E42
页数：1
相关论文
共 50 条
  • [1] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Swiha, Mina M.
    Sutherland, Duncan E. K.
    Sistani, Golmehr
    Khatami, Alireza
    Abazid, Rami M.
    Mujoomdar, Amol
    Wiseman, Daniele P.
    Romsa, Jonathan G.
    Reid, Robert H.
    Laidley, David T.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 225 - 236
  • [2] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Mina M. Swiha
    Duncan E. K. Sutherland
    Golmehr Sistani
    Alireza Khatami
    Rami M. Abazid
    Amol Mujoomdar
    Daniele P. Wiseman
    Jonathan G. Romsa
    Robert H. Reid
    David T. Laidley
    [J]. Journal of Cancer Research and Clinical Oncology, 2022, 148 : 225 - 236
  • [3] Peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE following liver directed therapy (LDT) in neuroendocrine tumors (NETs): Hepatotoxicity and impact on progression-free survival (PFS)
    Badawy, M.
    Halfdanarson, T.
    Johnson, G.
    Hobday, T.
    Young, J.
    Packard, A.
    Thorpe, M.
    Sandhya, M.
    Eiring, R.
    Patton, C.
    Gansen, D.
    Kendi, A.
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 174 - 174
  • [4] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Yeokyeong Shin
    Bo Hyun Moon
    Baek-Yeol Ryoo
    Heung-Moon Chang
    Kyu-pyo Kim
    Yong Sang Hong
    Tae Won Kim
    Jin-Sook Ryu
    Yong-il Kim
    Changhoon Yoo
    [J]. Targeted Oncology, 2024, 19 : 41 - 49
  • [5] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Shin, Yeokyeong
    Moon, Bo Hyun
    Ryoo, Baek-Yeol
    Chang, Heung-Moon
    Kim, Kyu-pyo
    Hong, Yong Sang
    Kim, Tae Won
    Ryu, Jin-Sook
    Kim, Yong-il
    Yoo, Changhoon
    [J]. TARGETED ONCOLOGY, 2024, 19 (01) : 41 - 49
  • [6] Serial Dosimetry in Peptide Receptor Radionuclide Therapy using Lu-177 DOTATATE or Lu-177 DOTATOC in the same Patient
    Schuchardt, C.
    Kulkarni, H.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S139 - S139
  • [7] Dosimetry using Lu-177 DOTATATE, Lu-177 HA-DOTATATE and Lu-177 DOTATOC: Comparative Results in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT)
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Shafaei, S.
    Kropf, S.
    Wester, H. J.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S224 - S225
  • [8] Peptide Receptor Radionuclide Therapy with Lu-177 DOTATATE in patients with somatostatin receptor positive tumours
    Kamaleshwaran, K.
    Sudhakar, N.
    Paulvannan, S.
    Vysakh, M.
    Shinto, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S722 - S722
  • [9] Peptide Receptor Radionuclide Therapy Using 177 Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment
    Kalantarhormozi, Mohammadreza
    Hassanzadeh, Samaneh
    Rekabpour, Seyed Javad
    Ravanbod, Mohammad Reza
    Jafari, Esmail
    Amini, AbdulLatif
    Dadgar, Habibollah
    Mahmoudpour, Mehdi
    Nabipour, Iraj
    Jokar, Narges
    Assadi, Majid
    [J]. WORLD JOURNAL OF NUCLEAR MEDICINE, 2022, 21 (03) : 215 - 221
  • [10] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)
    Navarro Martin, M.
    Teran Brage, E.
    Campana-Diaz, E.
    Garcia-Talavera, P.
    Reguera Puertas, P.
    Rama-Alonso, S.
    Garijo-Martinez, M. C.
    Felix, L. C.
    Diaz Sanchez, P.
    Vidal Tocino, R.
    Fonseca Sanchez, E.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
12345